BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22377565)

  • 1. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
    Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
    BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
    Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
    J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
    Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
    Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
    Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
    PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
    Pokataev I; Kudaibergenova A; Artemyeva A; Popova A; Rumyantsev A; Podluzhny D; Kudashkin N; Fedyanin M; Tryakin A; Tjulandin S
    J Gastrointest Cancer; 2019 Sep; 50(3):478-484. PubMed ID: 29675723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma.
    Anstadt EJ; Carmona R; Berlin E; Yegya-Raman N; Venigalla S; Reddy V; Williams GR; Leibensperger MR; Wojcieszynski A; Baumann BC; Lee MK; Plastaras JP; Furth EE; Mell LK; Metz JM; Ben-Josef E
    Cancer; 2024 Feb; 130(3):476-484. PubMed ID: 37823514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
    Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
    J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
    Herman JM; Jabbour SK; Lin SH; Deek MP; Hsu CC; Fishman EK; Kim S; Cameron JL; Chekmareva M; Laheru DA; Narang AK; Pawlik TM; Hruban RH; Wolfgang CL; Iacobuzio-Donahue CA
    Pancreas; 2018 Feb; 47(2):208-212. PubMed ID: 29329157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.
    Singhi AD; Foxwell TJ; Nason K; Cressman KL; McGrath KM; Sun W; Bahary N; Zeh HJ; Levy RM; Luketich JD; Davison JM
    Am J Surg Pathol; 2015 Apr; 39(4):487-95. PubMed ID: 25634752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
    Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Volkan Adsay N; Curran WJ; Landry JC; Maithel SK; Yu DS
    Oncogene; 2014 Nov; 33(47):5450-6. PubMed ID: 24276239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma.
    Wu H; Zhu L; Zhang H; Shi X; Zhang L; Wang W; Xue H; Liang Z
    PLoS One; 2015; 10(2):e0116803. PubMed ID: 25679210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
    Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
    World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
    Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
    J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.